NOR-Gout study shows Non-adherence to urate lowering therapy after 5 years is related to poor gout outcomes. 5-year Observational study of 163 patients showed overall good ULT adherence but nonadherent had more flares (33 vs 10%) & less at target (45 vs 87%)… https://t.co/xuIjBiuFHF https://t.co/fmqkCOYayP

Stratified Cancer Screening in Dermatomyositis The International Myositis Assessment and Clinical Studies Group (IMACS) have published evidence and consensus based cancer screening guidelines for patients with idiopathic inflammatory myopathies, including dermatomyositis.… https://t.co/IQ8JpUMtnn https://t.co/eEM2uuQbKB

UCB released topline results of a phase 3b H2H "BE BOLD" RCT of bimekizumab (anti-IL17) vs rizankizumab (anti-IL23) in 550 active adult #PsA pts - at wk 16 inhibition of IL-17A/F was superior to IL-23 using the ACR50 primary endpoint. https://t.co/aWnHYefS2C https://t.co/2Vft5fouFv

Pooled data from #PsA (n=914) & #AS (n=372) RCTs looked at outcomes in smokers (37% & 48%). Current or past smoking had NO EFFECT on outcomes (MDA, ACR50, ASAS40, ASDAS), but incr odds of D/C & some SAE (SIE) but not MACE, HZ, VTE https://t.co/WRflSVO3Ig https://t.co/YMI5YCT0QK

Study of 866 #AS pts shows those w/ lower socioeconomic status (SES) had longer Dx delay, higher BME, more structural damage, & permanent disability (31% vs 13%), compared to high SES AS pts; despite similar use of bDMARDs betw groups. https://t.co/x0dfFACUz9 https://t.co/tOmhE9vGiH

Diagnostic delay of 7.4 yrs (median 4yrs) in axSpA. An Int’l IMAS cross-sectional online Pt. survey (2017–22) 5,557 axSpA pts (27 countries). The highest delay in S Africa & lowest in Asia. Longer Dx delay assoc w/ younger age, female, rheumatologist Dx, # HCPs, & Hx uveitis… https://t.co/sqf2uamKG6 https://t.co/JUseWzbwUh

British Society Guidelines for Managing Behçet’s Disease An exhaustive, full read guideline from the British Association of Dermatologists (BAD) and the British Society for Rheumatology (BSR) on the management and treatment of Behçet’s disease (BD) in 2024 has been published in… https://t.co/4Q1Ac60Dyp https://t.co/Qj3sQQ8SnJ

Bimekizumab FDA Approved for Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis UCB announced today that the U.S. Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx) for the treatment of 3 chronic inflammatory… https://t.co/aITAeYuJxv https://t.co/tAPFfshPSs

In utero exposure to upadacitinib review w/ 128 maternal exposures & known outcomes; 80 from RCTs & 48 Postmarketing Pregs. From RCTs - 54-46% live births, 24-38% spont. abortions, 21-15% elective Ab, 1-2% ectopics from RCTs & Postmarketing. No evidence of teratogenicity… https://t.co/s3VJspI59V https://t.co/tV48sKyF8x

Mycophenolate in New-Onset SLE How aggressively do you treat newly diagnosed new-onset systemic lupus erythematosus (SLE), or should you wait for organ involvement? A trial of early use of mycophenolate mofetil (MMF), in addition to prednisone and hydroxychloroquine, decreased… https://t.co/TGLGJAg8SA https://t.co/392tItoTn7

Progression of Undifferentiated Arthritis to Inflammatory Arthritis https://t.co/Ozr8jPnAcx https://t.co/Jctal4xznB

EULAR/PReS Still's Disease Management Recommendations Since 2022, EULAR and the Paediatric Rheumatology European Society (PReS) have been working to establish clinical practice guidelines for the diagnostics and management of systemic juvenile idiopathic arthritis (sJIA) and… https://t.co/JZidoWEZSq https://t.co/miwnaw5BZ3